跳至主要内容
临床试验/ACTRN12611001038987
ACTRN12611001038987尚未招募1 期

Randomised, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of BMS-929075 in Healthy Subjects.

Bristol-Myers Squibb Company0 个研究点目标入组 96 人开始时间: 2011年10月4日最近更新:
适应症

试验速览

阶段
1 期
状态
尚未招募
入组人数
96

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Randomised controlled trial
主要目的
Treatment
盲法
Blinded (masking used)

入排标准

年龄范围
18 Years 至 49 Years(—)
性别
All

入选标准

  • Healthy men and women ages 18 to 49
  • Body Mass Index (BMI) of 18 to 32kg/m2

排除标准

  • Any significant acute or chronic medical illness, including any:
  • - liver disease with laboratory screening results for ALT, AST or bilirubin > upper limit of normal
  • - gastrointestinal disease within the past 3 months.
  • Any major surgery, donation of blood or plasma to a blood bank or receipt of a blood transfusion within the past 4 weeks.
  • Smoking more than 10 cigarettes per day.
  • Healthy subjects with any of the following ECG findings prior to dosing:
  • - PR>/= 210 msec
  • - QRS>/= 120 msec
  • - QT>/= 500 msec
  • - QTcF>/+ 450 msec
  • Positive urine screen for drugs of abuse or positive screen for Hepatitis C, Hepatitis B or HIV.

研究者

相似试验

Placebo-Controlled, Single and Multiple Ascending... | 临床试验